Orchard Therapeutics Plc (ORTX) Reports In-Line Q1 EPS

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q1 EPS of ($0.51), in-line with the analyst estimate of ($0.51).

“I feel privileged to lead Orchard as we embark on this new chapter, which is rooted in fulfilling the powerful possibilities for HSC gene therapies beyond ultra-rare diseases,” said Bobby Gaspar, M.D., Ph.D., chief executive officer. “Moving forward, we are focusing on advancing therapies for high need and high value diseases, and our work in neurometabolic disorders is a clear example of this. We’re also excited to announce new research programs which we believe will demonstrate the breadth of the HSC platform approach.”

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c